We're investing almost £1 million in pioneering research projects
Date
News
Date
Scientists have shown a pioneering test could diagnose Parkinson's correctly in its early stages.
Date
We're investing in research into inflammation that could help develop drugs that slow the progression of Parkinson's, something no current medication can do.
Date
The first participant has been recruited to a pioneering clinical trial which is testing a new drug called NLX-112 to investigate its potential for people with Parkinson's.
Date
UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
Date
We've launched a new report, Nobody really knows us – the state of health and social care for people with Parkinson's-related dementia.
Date
We've developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
Date
We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Date
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson's.
Date
Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Date
Caroline Rassell has been appointed as our new Chief Executive. She brings 20 years of board experience in healthcare and government roles.